Literature DB >> 18382007

Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study.

Christine M Rousseau1, George N Ioannou, Jeffrey A Todd-Stenberg, Kevin L Sloan, Meaghan F Larson, Christopher W Forsberg, Jason A Dominitz.   

Abstract

OBJECTIVES: We examined the association between race and hepatitis C virus (HCV) evaluation and treatment of veterans in the Northwest Network of the Department of Veterans Affairs (VA).
METHODS: In our retrospective cohort study, we used medical records to determine antiviral treatment of 4263 HCV-infected patients from 8 VA medical centers. Secondary outcomes included specialty referrals, laboratory evaluation, viral genotype testing, and liver biopsy. Multiple logistic regression was used to adjust for clinical (measured through laboratory results and International Classification of Diseases, Ninth Revision, codes) and sociodemographic factors.
RESULTS: Blacks were less than half as likely as Whites to receive antiviral treatment (odds ratio [OR]=0.38; 95% confidence interval [CI]=0.23, 0.63). Both had similar odds of referral and liver biopsy. However, Blacks were significantly less likely to have complete laboratory evaluation (OR=0.67; 95% CI=0.52, 0.88) and viral genotype testing (OR=0.68; 95% CI=0.51, 0.90).
CONCLUSIONS: Race is associated with receipt of medical care for various medical conditions. Further investigation is warranted to help understand whether patient preference or provider bias may explain why HCV-infected Blacks were less likely to receive medical care than Whites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18382007      PMCID: PMC2374801          DOI: 10.2105/AJPH.2007.113225

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  50 in total

1.  Differences, disparities, and biases: clarifying racial variations in health care use.

Authors:  Saif S Rathore; Harlan M Krumholz
Journal:  Ann Intern Med       Date:  2004-10-19       Impact factor: 25.391

2.  Racial differences in the relationship between hepatitis C infection and iron stores.

Authors:  George N Ioannou; Jason A Dominitz; Noel S Weiss; Patrick J Heagerty; Kris V Kowdley
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

3.  A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection.

Authors:  Andrew J Muir; Dawn Provenzale
Journal:  J Clin Gastroenterol       Date:  2002-03       Impact factor: 3.062

4.  Racial disparity in the use of atypical antipsychotic medications among veterans.

Authors:  Laurel A Copeland; John E Zeber; Marcia Valenstein; Frederic C Blow
Journal:  Am J Psychiatry       Date:  2003-10       Impact factor: 18.112

5.  Prevalence of Hepatitis C virus infection in a sample of homeless veterans.

Authors:  Rani A Desai; Robert A Rosenheck; Vincent Agnello
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2003-07       Impact factor: 4.328

6.  Psychiatric disorders among veterans with hepatitis C infection.

Authors:  Hashem B el-Serag; Mark Kunik; Peter Richardson; Linda Rabeneck
Journal:  Gastroenterology       Date:  2002-08       Impact factor: 22.682

7.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

8.  Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

Authors:  Lennox J Jeffers; William Cassidy; Charles D Howell; Sylvia Hu; K Rajender Reddy
Journal:  Hepatology       Date:  2004-06       Impact factor: 17.425

9.  National Hepatitis C Surveillance Day in the Veterans Health Administration of the Department of Veterans Affairs.

Authors:  Gary A Roselle; Linda H Danko; Stephen M Kralovic; Loretta A Simbartl; Kenneth W Kizer
Journal:  Mil Med       Date:  2002-09       Impact factor: 1.437

10.  Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.

Authors:  Andrew J Muir; Jeffrey D Bornstein; Paul G Killenberg
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  17 in total

1.  Outcomes of treatment for hepatitis C virus infection by primary care providers.

Authors:  Sanjeev Arora; Karla Thornton; Glen Murata; Paulina Deming; Summers Kalishman; Denise Dion; Brooke Parish; Thomas Burke; Wesley Pak; Jeffrey Dunkelberg; Martin Kistin; John Brown; Steven Jenkusky; Miriam Komaromy; Clifford Qualls
Journal:  N Engl J Med       Date:  2011-06-01       Impact factor: 91.245

2.  Racial-Ethnic Disparities in Uptake of New Hepatitis C Drugs in Medicare.

Authors:  Jeah Jung; Roger Feldman
Journal:  J Racial Ethn Health Disparities       Date:  2016-12-07

3.  Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy.

Authors:  Manhal Izzy; Ghalib Jibara; Aws Aljanabi; Mustafa Alani; Emily Giannattasio; Hina Zaidi; Zaid Said; Paul Gaglio; Allan Wolkoff; John F Reinus
Journal:  J Clin Exp Hepatol       Date:  2016-03-12

4.  Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents.

Authors:  Christopher Woodrell; Jeffrey Weiss; Andrea Branch; Donald Gardenier; Katherine Krauskopf; Natalie Kil; Harold Paredes; Kian Bichoupan; Keith Sigel
Journal:  J Addict Med       Date:  2015 Sep-Oct       Impact factor: 3.702

5.  Racial differences in hepatitis C treatment eligibility.

Authors:  Michael T Melia; Andrew J Muir; Jonathan McCone; Mitchell L Shiffman; John W King; Steven K Herrine; Greg W Galler; Joseph R Bloomer; Frederick A Nunes; Kimberly A Brown; Kevin D Mullen; Natarajan Ravendhran; Reem H Ghalib; Navdeep Boparai; Ruiyun Jiang; Stephanie Noviello; Clifford A Brass; Janice K Albrecht; John G McHutchison; Mark S Sulkowski
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

6.  Hepatitis C screening: getting it right.

Authors:  Brian R Edlin
Journal:  Hepatology       Date:  2012-12-24       Impact factor: 17.425

7.  Assessing Racial Disparities in HCV Infection and Care Outcomes in a Southern Urban Population.

Authors:  Keanan McGonigle; Tess Carley; Clarissa Hoff
Journal:  J Racial Ethn Health Disparities       Date:  2017-12-29

8.  Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.

Authors:  Julia L Marcus; Leo B Hurley; Scott Chamberland; Jamila H Champsi; Laura C Gittleman; Daniel G Korn; Jennifer B Lai; Jennifer O Lam; Mary Pat Pauly; Charles P Quesenberry; Joanna Ready; Varun Saxena; Suk I Seo; David J Witt; Michael J Silverberg
Journal:  Public Health Rep       Date:  2018-05-11       Impact factor: 2.792

9.  Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010.

Authors:  Rania A Tohme; Jian Xing; Youlian Liao; Scott D Holmberg
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

10.  Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Hashem B El-Serag; Susan Frayne; Jack Clark; Yumei Cao; Thomas Taylor; Donna Smith; Donna White; Steven M Asch
Journal:  Clin Infect Dis       Date:  2016-04-30       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.